• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World

    EC election ‘open, honest and fair’, says David Lok

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    Fossil fuels still missing from latest COP31 draft

    HK-Chile working-holiday scheme to start next year

    HK to contribute to global bay area cooperation: FS

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World

    EC election ‘open, honest and fair’, says David Lok

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    Fossil fuels still missing from latest COP31 draft

    HK-Chile working-holiday scheme to start next year

    HK to contribute to global bay area cooperation: FS

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis

PR Newswire by PR Newswire
1 May 2025
in PR Newswire
0
Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

SUZHOU, China, May 1, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026 (Study ID: KN026-001) in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)), has completed the first interim analysis and met the pre-specified primary endpoint of progression-free survival (PFS) as evaluated by an Independent Data Monitoring Committee (IDMC), with both statistical significance and clinical relevance.

KN026-001 is a randomized, multicenter, Phase II/III clinical study designed to evaluate the efficacy of KN026 in combination with chemotherapy inpatients with HER2-positive advanced, unresectable, or metastatic GC (including GEJ) who have failed first-line treatment. Part 2 of KN026-001 is a randomized, double-blind, placebo-controlled Phase III study. Patients with HER2-positive GC (including GEJ) who had previously received and failed at least first line standard treatment were enrolled and randomized 1: 1 to receive either KN026 in combination with chemotherapy or placebo in combination with chemotherapy. The primary endpoints of this study are PFS and overall survival (OS) as assessed by the Independent Review Committee (IRC).

The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease progression or death, and showed a trend toward OS benefit. Detailed data from this study will be presented at an upcoming international academic conference.

About KN026

KN026 is an anti-HER2 bispecific antibody independently developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). KN026 can simultaneously bind two non-overlapping epitopes of HER2, leading to HER2 signal blockade. KN026 has demonstrated better tumor inhibition in HER2-positive tumor cell lines compared with trastuzumab and pertuzumab in combination. Additionally, KN026 has also shown inhibitory effect on tumor cells with trastuzumab-resistant cell lines.

The results of multiple clinical studies in different stages showed that KN026 has significant anti-tumor activities, even in heavily pretreated patients with HER2-positive breast cancer (BC) and gastric cancer (GC), including those with prior anti-HER2 treatment. Currently, several pivotal clinical trials of KN026 for the second-line and beyond treatment of HER2-positive GC/gastroesophageal junction cancer (GEJ), the first-line treatment of HER2-positive BC, neoadjuvant treatment for HER2-positive BC are being conducted. KN026 in combination with chemotherapy for the treatment of patients with HER2-positive GC (including GEJ) who have failed first-line standard treatment was granted breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA).

In August 2021, the Company entered an agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), for the development and commercialization of KN026 in Mainland China, pursuant to which, JMT-Bio was granted exclusive license rights of KN026 for the development and commercialization in the indications of BC an GC/GEJ in Mainland China (excluding Hong Kong, Macau and Taiwan).

About Alphamab Oncology

Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a differentiated and globally competitive product portfolio, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.

The Company has one product approved for marketing (Envafolimab, the world’s first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs to benefit patients.

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

Finnate by Centelon Lets Australian Lenders Test Its Loan Servicing Platform Without a Sales Demo

Finnate by Centelon Lets Australian Lenders Test Its Loan Servicing Platform Without a Sales Demo

22 November 2026
Finnate by Centelon Lets Australian Lenders Test Its Loan Servicing Platform Without a Sales Demo

Finnate by Centelon Lets Australian Lenders Test Its Loan Servicing Platform Without a Sales Demo

22 November 2026
  • Trending
  • Comments
  • Latest
Newgen reports Revenue of ₹357 crores in Q1 FY’27, up 11% Q1 YoY; Profit After Tax at ₹63 crores, up 26% Q1 YoY

Newgen Software and the Asian Institute of Digital Finance Forge Strategic Partnership to Shape the Future of Enterprise AI

10 November 2026

World Winter Sports Expo 2026 Opens, Charting a New Decade for Ice and Snow and Outdoor Industries

17 October 2026

HK five-year plan offers UK long-term prospects: CE

10 November 2026
Patriot Launches AI Matrix SSD and DRAM Series Engineered for Local AI Workloads

Patriot Launches AI Matrix SSD and DRAM Series Engineered for Local AI Workloads

19 November 2026

EC election ‘open, honest and fair’, says David Lok

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

22 November 2026

Fossil fuels still missing from latest COP31 draft

22 November 2026

Recent News

EC election ‘open, honest and fair’, says David Lok

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

22 November 2026

Fossil fuels still missing from latest COP31 draft

22 November 2026
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com